Banner: investors

News Releases

PURE Bioscience to Present at the 28th Annual ROTH Capital Partners Conference

February 29, 2016

Discussion of FDA Approved PURE Control® to Combat Foodborne Illnesses

 SAN DIEGO (Feb 29, 2016) – PURE Bioscience, Inc. (OTCQB: PURE), creator of the FDA approved, patented silver dihydrogen citrate (SDC) antimicrobial, announced today the Company will present at the 28th Annual ROTH Capital Partners Conference on March 14, 2016 in Orange County, CA.

 Hank R. Lambert, CEO, will present on Monday, March 14th at 1:00pm PDT. Lambert will discuss the two recent FDA approvals of its Food Contact Notifications (FCNs) for SDC antimicrobial use in (a) fresh produce processing and (b) raw poultry processing:

  • SDC is a highly effective, non-toxic food safety solution.

    • PURE Control® addresses a $650 million combined US produce and poultry processing aid market.

  • SDC test results demonstrate materially significant reduction in Salmonella, Listeria and E. coli contamination in fresh produce; and dramatic reduction of Salmonella contamination in raw poultry.

 The presentation will be webcast live with slides (and available for replay) and can be accessed on the Company's website, http://www.purebio.com/investors/events-presentations/.

 About ROTH Capital Partners

ROTH Capital Partners, LLC (ROTH), is a relationship-driven investment bank focused on serving emerging growth companies and their investors. As a full-service investment bank, ROTH provides capital raising, M&A advisory, analytical research, trading, market-making services and corporate access. Headquartered in Newport Beach, CA, ROTH is privately-held and employee owned, and maintains offices throughout the U.S. For more information on ROTH, please visit www.roth.com.

About PURE Bioscience, Inc. 

PURE Bioscience, Inc. is focused on developing and commercializing our proprietary antimicrobial products primarily in the food safety arena -- providing solutions to the health and environmental challenges of pathogen and hygienic control. Our technology platform is based on patented stabilized ionic silver, and our initial products contain silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour residual protection and formulates well with other compounds. As a platform technology, SDC is distinguished from existing products in the marketplace because of its superior efficacy, reduced toxicity and it mitigates bacterial resistance. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at www.purebio.com.

 Forward-looking Statements   

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause our actual results to differ materially from the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the Company’s failure to implement or otherwise achieve the benefits of its proposed business initiatives and plans; acceptance of the Company's current and future products and services in the marketplace, including acceptance of the Company’s PURE Control as a fresh produce processing aid and the Company’s ability to convert successful evaluations into customer orders; the ability of the Company to develop effective new products and receive required regulatory approvals for such products, including the required data and regulatory approvals required to use its SDC-based technology as a direct food contact processing aid in raw poultry and raw meat processing; competitive factors; dependence upon third-party vendors, including to manufacture its products; and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission (the SEC), including its Form 10-K for the fiscal year ended July 31, 2015 and its Form 10-Q for the first quarter ended October 31, 2015. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. 

 

Contacts:

Hank Lambert, CEO                           Terri MacInnis, VP of IR                      Tom Hemingway       

PURE Bioscience, Inc.                         Bibicoff + MacInnis, Inc.                     Redwood Investment Group

619-596-8600 ext.103                         818-379-8500                                       714-978-4425

hlambert@purebio.com                     terri@bibimac.com                            tomh@redwoodfin.com